Avantec Vascular Secures FDA Clearance for DVT Thrombectomy System

Avantec Vascular, a consolidated subsidiary of Nipro Corporation based in California, has received FDA 510(k) clearance for its DVT-Focused Thrombectomy System. This new system, aimed at treating deep venous thrombosis (DVT), utilizes a combination of mechanical and aspiration methods to remove blood clots from the peripheral venous system. Avantec plans an initial limited market launch in the United States in 2026, with broader commercialization to follow.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Nipro Corporation published the original content used to generate this news brief on February 04, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.